{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Readind the Scraped Data and filtering the needed things"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import json\n",
    "\n",
    "data = []\n",
    "with open('dataScraped.json') as f:\n",
    "    for line in f:\n",
    "        data.append(json.loads(line))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "2\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "3\n",
      "-----\n",
      "I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "4\n",
      "-----\n",
      "Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "5\n",
      "-----\n",
      ".@VirusesImmunity &amp; Anna Marie Pyle: A stem loop RNA that stimulates RIG-I activation delays tumor growth, extends survival, and prevents tumor recurrence. JEM‚Äôs cancer collection for #AACR20 (https://t.co/G1mQsSpTaZ) has summaries of articles in this PDF: https://t.co/Hec3sDfz71 https://t.co/opwHDK5OAQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "6\n",
      "-----\n",
      "Pre existing ESR1 mutations in early stage primary breast cancer predict failure of endocrine therapy and poor OS. This is important and should guide how we think about ER+ breast cancer. #aacr20 https://t.co/DC3ROEJt4l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "7\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "8\n",
      "-----\n",
      "TMB is an #immunotherapy biomarker with tumor type agnostic potential. The use of #TMB has been hindered by the fact that commercial labs measure TMB differently. Pleased to see the hard work of the TMB harmonization project presented today at #AACR20 and published in #JITC. https://t.co/w2AUTikbaM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "9\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "10\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert üö®are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2‚É£.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "11\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "12\n",
      "-----\n",
      "‚ÄúOur preclinical data suggest that IPN60090 may be effective in underserved groups of patients who need better treatment options,‚Äù says our Dr. Jeffrey Kovacs: https://t.co/nAcAdjEdXQ #AACR20 #CancerMoonshot #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "13\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "14\n",
      "-----\n",
      "Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "15\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "16\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "17\n",
      "-----\n",
      "Important summary of key #COVID19nCancer data from #AACR2020. Thanks @CharuAggarwalMD\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "18\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "19\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "20\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here‚Äôs a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "21\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "22\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "23\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "24\n",
      "-----\n",
      "Nice presentation by Dr Sridhar (AstraZeneca) showing that tertiary lymphoid structures (assessed by gene signatures expression) are associated with response to anti-PD-L1 durvalumab in #NSCLC and UC, extending our results from soft tissue sarcoma and melanoma. #AACR20 https://t.co/ZWZ30ATRIF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "25\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "26\n",
      "-----\n",
      "It would be interesting to know whether the same gene expression pattern is seen across different tumor types.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "27\n",
      "-----\n",
      "Okay, I was not going to announce this till we actually had a cure but here goes: @Aiims1742  @VivekSubbiah and @UroDocAsh have formed a secret society in Harris County. \n",
      "\n",
      "Come join us at happy hour April 1, 2021 to learn what we have been up to @WSJ #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "28\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "29\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "30\n",
      "-----\n",
      "Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "31\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "32\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33\n",
      "-----\n",
      "CONGRESS | #AACR20 | Yuan-kai Shi presents results from a phase II trial of geptanolimab (GB226), an anti PD-1 humanized, monoclonal antibody, in patients with R/R PTCL #lymsm https://t.co/WMsnNysH0Z\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "34\n",
      "-----\n",
      "You can never be too respectful, so always err on the side of showing more, not less, respect. #pallonc #oncology #hapc #nursing\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "35\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "36\n",
      "-----\n",
      "Catching some of the @AACR virtual meeting today, super cool stuff. Makes me *very* excited for future virtual conferences! #AACR20 \n",
      "\n",
      "PS Fantastic discussion of social determinants of health during the #COVID19 session. Dont miss!\n",
      "\n",
      "PPS Virtual @roecsg in &lt;3 weeks what up! üéâü•≥üòÄ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "37\n",
      "-----\n",
      "„Äê#AACR20 COVID-19„Å®„Åå„ÇìÂåªÁôÇ„ÅÆ„Éó„É¨„Éä„É™„Éº„ÅÆÊ¶ÇË¶Å„Å®ÊÑüÊÉ≥, part 2„Äë\n",
      "COVID-19ÔºÜ„Åå„Çì„Å´„Å™„Å£„Åü„Å®„Åç„ÅÆ‰∫àÂæå‰∏çËâØ„ÅÆ„É™„Çπ„ÇØ\n",
      "- Áôå„ÅåËÇ∫„Å´Ëª¢Áßª„Åó„Å¶„ÅÑ„Çã„ÅãËÇ∫„Åå„Çì„Åß„ÅÇ„Çã\n",
      "- ARDS\n",
      "- Â•Ω‰∏≠ÁêÉÊ∏õÂ∞ëÁóá\n",
      "- ÔºëÔºîÊó•‰ª•ÂÜÖÂåñÂ≠¶ÁôÇÊ≥ï\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "38\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "39\n",
      "-----\n",
      "„Äê#AACR20 COVID-19„Éó„É¨„Éä„É™„Éº„ÅÆÊ¶ÇË¶Å„Å®ÊÑüÊÉ≥, part 3„ÄëÁô∫Ë°®„Éá„Éº„Çø„ÅØ„Åæ„Å†Â∞è„Åï„Åè„ÄÅÈÅ∏Êäû„Éê„Ç§„Ç¢„Çπ„Åå„ÅÇ„Çã„Åã„ÇÇ„ÄÇÂêÑÂõΩ„ÅÆÁµåÈ®ì„Åå„Åã„Å™„ÇäÁï∞„Å™„Å£„Å¶„ÅÑ„Çã„Åå„ÄÅ„Åì„Çå„ÅØ„Éá„Éº„Çø„Éº„ÅÆÂèéÈõÜÊñπÊ≥ï„ÅåÁï∞„Å™„Çã„Åü„ÇÅ„Å†„Çç„ÅÜ„Åã„ÄÇ ÁñæÊÇ£Âà•„Ç¨„Ç§„Éâ„É©„Ç§„É≥„ÅÆÂøÖË¶ÅÊÄß„ÇíÊÑü„Åò„Åü„ÄÇ„Åå„ÇìÊÇ£ËÄÖÂêë„Åë„ÅÆÊÑüÊüì„Åô„Çã„É™„Çπ„ÇØ„ÇíÂÆöÁæ©„Åô„Çã„Ç¢„É´„Ç¥„É™„Ç∫„É†„ÅåÂøÖË¶Å„Åß„ÅÇ„Çã„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "40\n",
      "-----\n",
      "#AACR20 delighted to share that my small observation/formula‚ûóis now published.üí°Small but novel finding. \n",
      "\n",
      "üëâüèºWhat if you could calculate the üî¢CA-19-9/CEA ratio &amp; it could identify üß¨BRAFV600E MSS üÜö MSI-High üÜö Others. Simple, rapid, &amp; cheap. \n",
      "\n",
      "#CRCSM üìÉhttps://t.co/7j0v23E2pq https://t.co/t359VmAK1n\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "41\n",
      "-----\n",
      "„Äê#AACR20 COVID-19„Å®„Åå„ÇìÂåªÁôÇ„ÅÆ „Éó„É¨„Éä„É™„Éº„ÅÆÊ¶ÇË¶Å„Å®ÊÑüÊÉ≥, part 1„Äë\n",
      "COVID-19„ÅÆÊÑüÊüì„É™„Çπ„ÇØ„ÅåÈ´ò„Åè„Å™„Å£„ÅüË¶ÅÂõ†„ÄÇ\n",
      "- 3„É∂Êúà‰ª•ÂÜÖ„ÅÆÂåñÂ≠¶ÁôÇÊ≥ï\n",
      "- PS„Åå‰Ωé„ÅÑÔºöËôöÂº±„Å™ÊÇ£ËÄÖ\n",
      "- Á§æ‰ºöÁµåÊ∏àÁöÑÂú∞‰Ωç„Åå‰Ωé„ÅÑ\n",
      "- Ë°ÄÊ∂≤Â≠¶ÁöÑÊÇ™ÊÄßËÖ´Áòç\n",
      "- ÁâπÂÆö„ÅÆÁ®ÆÈ°û„ÅÆÊ≤ªÁôÇÊ≥ï„ÅåÁõÆÁ´ã„Åü„Å™„Åã„Å£„Åü„ÄÇÂÖçÁñ´ÁôÇÊ≥ï„ÅØ„É™„Çπ„ÇØ„Å®„Åó„Å¶Âá∫„Å¶„Åì„Å™„Åã„Å£„Åü„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "42\n",
      "-----\n",
      "Á¢∫„Åã„Å™ÊÉÖÂ†±„ÄÄ#CancerX\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "43\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "44\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "45\n",
      "-----\n",
      "Thanks for the coverage of our @SWOG trial results presented at #AACR20, @jasoncology and @OncLive!\n",
      "https://t.co/av8vGk7toM via @onclive\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "46\n",
      "-----\n",
      "Dr. Chris Abbosh's introduction very nicely framed the importance of intervention at the MRD stage. #LiquidBiopsy could allow us to shift the therapeutic window to when disease burden is earlier + guide targeted therapy selection. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "47\n",
      "-----\n",
      "@ivybelkins @AACRFoundation Such a hot button for me too. People may have the ability to \"reduce their risk\" of cancer but true prevention is still not possible in most cases. To pretend otherwise is detrimental and creates stigma and shaming.  #WordsMatter #lcsm #bcsm #AACR20 #AACR2020\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "48\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "49\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "51\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "52\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "53\n",
      "-----\n",
      "New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "54\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "55\n",
      "-----\n",
      "Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, and medical oncologist Mihaela Cristea, M.D.\n",
      "\n",
      "Dr. Fong: https://t.co/taB7ae9TeQ\n",
      "Dr. Cristea: https://t.co/XdWaJgt4tP https://t.co/VqLdJWiDx7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "56\n",
      "-----\n",
      "RT cityofhope: Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Dep‚Ä¶\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "57\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "58\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "59\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "60\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "61\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "‚¨ÜÔ∏è pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "62\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "63\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "64\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "65\n",
      "-----\n",
      "#AACR20 üí≠I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose ü©∏üß¨MRD‚ûïsubset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be highüìà. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "66\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert üö®are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2‚É£.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "67\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "68\n",
      "-----\n",
      "Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL @DanaFarber @AACR #lymsm #AACR20 https://t.co/sZhSb8dbdB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "69\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "70\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "71\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @CharuAggarwalMD üë©‚Äç‚öïÔ∏èfrom @PennCancer  Virtually Live at #AACR20 discussing globalüåèpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino üáÆüáπ&amp; The French experience by @barlesi from @GustaveRoussy üá´üá∑\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "72\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "73\n",
      "-----\n",
      "Early detection at #AACR20: David Thiel @MayoClinic speaks about test to predict cancer and organ of origin w/cfDNA. \"Intention is to use in addition to testing based on screening guidelines (not on its own)\" -- wondering why not for all patients? #lcsm @lungcancer @EGFRResisters https://t.co/uzEWy6WNWR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "74\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "75\n",
      "-----\n",
      "Technical challenges exist in using #liquidbiopsies to screen everyone for cancer, in addition to cost issues.  #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/V3xu4uyIHW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "76\n",
      "-----\n",
      "Check out this video by the amazing Dr. @CharuAggarwalMD. \n",
      "\n",
      "#OncoAlert \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "77\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert üö®Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‚ÄºÔ∏è https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "78\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "79\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @LeciaSequist üë©‚Äç‚öïÔ∏èof @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer \n",
      "Edited: @weoncologists https://t.co/U9ZPHynuZA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "80\n",
      "-----\n",
      "#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "81\n",
      "-----\n",
      "#OncoAlert #AACR20 Serial scans show #COVID19 related lung changes. Note the fibrosis emerging at day 25. Will long-term sequela impact respiratory function, quality of life? Will this vary by prior lung pathology, prior radiation, prior pneumonitis, etc? https://t.co/XrcRUiRe7e\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "82\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "83\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert üö®Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‚ÄºÔ∏è https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "84\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "85\n",
      "-----\n",
      "#AACR20 Dr. Domchek‚Äôs discussion of PARPi #EMBRACA:\n",
      "\n",
      "üóù no OS with olaparib or talazoparib in #bcsm, but PFS and tolerability ‚¨ÜÔ∏è\n",
      "\n",
      "‚ú®No diff by HR/TNBC, or by platinum, BUT benefit only w/ no chemo in MBC, not there 2nd/3rd line\n",
      "\n",
      "üîÄ crossover confounds OS, 32% got PARP @OncoAlert https://t.co/E9chuSZtnK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "86\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "87\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "88\n",
      "-----\n",
      "Cancer patients like triple-negative #breastcancer survivor @deb_silverman are among those most vulnerable to #COVID19: https://t.co/4M0pycC7i1 @washingtonpost #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "89\n",
      "-----\n",
      "@IpshitaPrakash\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "90\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "91\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "92\n",
      "-----\n",
      "#OncoAlert #AACR20 TAK-788 safety: At 160mg qd, G3+ AE in 40%, 25% dose reduction, 50% interruption. G3+ diarrhea 18%. Given the history of drugs here, does dose intensity correlate with DOR? I'm interested in G2 toxicities, which are very relevant here. Any QOL data? #LCSM https://t.co/32yxkSYdLW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "93\n",
      "-----\n",
      "‚ÄúThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,‚Äù says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "94\n",
      "-----\n",
      "David Huntsman discusses role of ctDNA/liquid biopsies &amp; interestingly the potential benefits of the uses are greatly increased due to #COVID19. #AACR20 #LCSM https://t.co/VofP7CmZXH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "95\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "96\n",
      "-----\n",
      "Tertiary lymphoid structure (TLS) formation in NSCLC may predict response to immunotherapy (durvalumab) thru interaction with tumor micro-environment. Dr. Sriram Sridhar from AstraZeneca #AACR2020 #AACR20 #LCSM https://t.co/ywMmlw63gL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "97\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "98\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "99\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "100\n",
      "-----\n",
      "Yay B cells!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "101\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "102\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "103\n",
      "-----\n",
      "@theNCI is supporting #COVID19-related research efforts. Program announcements in this tweet. Please contact your program officer. #AACR2020 #AACR20 #LCSM https://t.co/1IKrsqoIJT\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "104\n",
      "-----\n",
      "Presentan resultados de ensayo cl√≠nico CIMAvax en congreso de Asociaci√≥n para la Investigaci√≥n del C√°ncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "105\n",
      "-----\n",
      "#AACR20 more on PARP‚õîÔ∏è #BRCA #DNA-Repair üß¨\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "106\n",
      "-----\n",
      "High yield data today at #AACR20 coming from my mentors and colleagues here at @MoffittNews #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "107\n",
      "-----\n",
      "The @CancerResrch #TMB Harmonization Project aims to align across panel TMB values estimated with different commercial tests to ensure consistency across TMB values... this effort is key to help identify patients who are more likely to benefit from #immunotherapies #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "108\n",
      "-----\n",
      "Very excited to see our #metanalysis from @ASCO_pubs #JCOGO presented at #AACR20 by @marinagarassino @HornLeora et al. #TERAVOLT team! @tm_parekh @ASCO @AACR @COVID19nCCC https://t.co/iOFHphGBZj\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "109\n",
      "-----\n",
      "Outstanding thread from @ADesaiMD #COVID19 #AACR20 @COVID19nCCC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "110\n",
      "-----\n",
      "Today‚Äôs #AACR20 presentation on #COVID19nCancer (and @CD_AACR paper) is the subject of a @lauriemcginley2 column. \n",
      "With a special cameo by @MDAndersonNews All Star physician scientist &amp; cancer survivor @deb_silverman #Bcsm @COVID19nCCC \n",
      "https://t.co/HiJ21w6Mq6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "111\n",
      "-----\n",
      "ctDNA measurement thru liquid biopsy over time (frm FLAURA study) predicts progression-free survival &amp; correlates w/ tumor size in EGFR-mutant NSCLC tx w/ osimertinib. Possibility fr monitoring during #COVID19? Dr. Martin Johnson frm Astra Zeneca #AACR2020 #AACR20 #LCSM https://t.co/5utKOMIMZc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "112\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "113\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "114\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "115\n",
      "-----\n",
      "Still catching up on #AACR20? CRI's @ArthurBrodsky shares highlights in #immunotherapy from Day 1. https://t.co/ep0pAZmNDb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "116\n",
      "-----\n",
      "Thanks to #AACR20 I don‚Äôt feel depressed going through my twitter feed for the first time in weeks!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "117\n",
      "-----\n",
      "Our @OncoAlert üö®colleague @itsnot_pink live from #AACR20 discussing EMBRACA trial led by @MDAndersonNews .Advanced #breastcancer patients w/ #BRCA mutation, talazoparib did not see improved OS compared to #chemotherapy \n",
      "However did see improved QOL‚ÄºÔ∏è#BCSM\n",
      "edited: @weoncologists https://t.co/9aMaP9tnXK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "118\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert üö®Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‚ÄºÔ∏è https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "119\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "120\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "121\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "122\n",
      "-----\n",
      "Dear #AACR20 We're #OncoAlert ‚öïÔ∏è: @CharuAggarwalMD @Alfdoc2 @Tony_Calles @agrothey @JTrentMDPhD @ChristianRolfo @TiansterZhang @StephenVLiu @guiperini @prat_aleix @marklewismd @FAndreMD @weldeiry @BK_radiation @sharp_lena @DrSGraff @DrDanielHeng @MKnoll_MD @marinagarassino\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "123\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "124\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "125\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "126\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "127\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "128\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "129\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "130\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "131\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "132\n",
      "-----\n",
      "Mobo on the move: EGFR exon 20 insertions are a blindspot in targeted therapy options for #NSCLC. Yesterday #Takeda announced #FDA breakthrough for Mobocertinib (TAK-788) in ex20ins mNSCLC. Today at #AACR20 they encored their 2019 #ASCO phase 1/2 data showing a 43% ORR. #lcsm https://t.co/b8JjMMyRIf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "133\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "134\n",
      "-----\n",
      "Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "135\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "136\n",
      "-----\n",
      "Still not where we need to be in stufying pts w #brainmets despite so much effort. We need pharma &amp; coop groups to include these pts! #btsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "137\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "138\n",
      "-----\n",
      "#AACR20üëáüèº#TwitterPoll ‚û°Ô∏è #COVID19 &amp; #Cancer #COVIDnCancer. \n",
      "Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer ‚ûïhome-drawü©∏üöë\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "139\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "140\n",
      "-----\n",
      "New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "141\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "142\n",
      "-----\n",
      "Never understood that either! @AACR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "143\n",
      "-----\n",
      "Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "144\n",
      "-----\n",
      "TIL Therapy Elicits Encouraging Activity in Advanced NSCLC @MoffittNews @AACR #lcsm #AACR20 https://t.co/qxwMwtrTrR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "145\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "146\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "147\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "148\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "149\n",
      "-----\n",
      "#AACR20 is now LIVE. Watch research presentations by City of Hope's Yuman Fong, M.D., the chief of the Department of Surgery; Kimlin Tam Ashing, Ph.D., the founding director of the Center of Community Alliance for Research &amp; Education, and medical oncologist Mihaela Cristea, M.D.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "150\n",
      "-----\n",
      "#AACR20 is now LIVE. Watch research presentations by City of Hope's Yuman Fong, M.D., the chief of the Department of Surgery; Kimlin Tam Ashing, Ph.D., the founding director of the Center of Community Alliance for Research &amp; Education, and medical oncologist Mihaela Cristea, M.D.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "151\n",
      "-----\n",
      "#AACR20üëáüèº#TwitterPoll ‚û°Ô∏è #COVID19 &amp; #Cancer #COVIDnCancer. \n",
      "Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer ‚ûïhome-drawü©∏üöë\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "152\n",
      "-----\n",
      "Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "153\n",
      "-----\n",
      "New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "154\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "155\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "156\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "157\n",
      "-----\n",
      "Still catching up on #AACR20? CRI's @ArthurBrodsky shares highlights in #immunotherapy from Day 1. https://t.co/ep0pAZmNDb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "158\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "159\n",
      "-----\n",
      ".@Nowak_Lab &amp; @trotmanlab: Identification of the phosphatase PHLPP2‚Äôs role in controlling MYC stability could have implications for many cancers. JCB‚Äôs cancer collection for #AACR20 (https://t.co/hgWqfffjWG) has new short summaries of articles: https://t.co/4RX37rq7jA https://t.co/Go7IWLoJZY\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "160\n",
      "-----\n",
      "Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "161\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "162\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here‚Äôs a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "163\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "164\n",
      "-----\n",
      "Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "165\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "166\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ https://t.co/OFppgUN3XK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "167\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "168\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "169\n",
      "-----\n",
      "@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm\n",
      "\n",
      "Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1\n",
      "\n",
      "Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant\n",
      "\n",
      "https://t.co/bLGxRlKKu1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "170\n",
      "-----\n",
      "This poster was actually the one I was watching when it struck me how awesome the individual poster video format is üòâ. Nicely presented @benweinbergmd #AACR20 #PancreaticCancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "171\n",
      "-----\n",
      "We are aiming to expand #PrecisionOncology into early-stage cancer, when #cancer is typically easier to cure. #AACR20 #AACR2020 https://t.co/dTrjwWZqge\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "172\n",
      "-----\n",
      "We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "173\n",
      "-----\n",
      "@SeanSachdevMD @subatomicdoc @_ShankarSiva @SBRT_CR @theabzlab @Prof_Nick_James @DrSpratticus I love the virtual format! My PI has funds to send me to conferences every 3 years. I've attended 2 conferences this week alone: #AACR20 and #TAGC20 The questions are lot better, since the moderator can group related questions and participants can \"vote up\" questions they like.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "174\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "175\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "176\n",
      "-----\n",
      "Next \"new drug on the horizon\" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.\n",
      "\n",
      "Currently recruiting patients with #ER+ #MBC. \n",
      "\n",
      "#BCSM #AACR20 \n",
      "https://t.co/7aWgt2Bv60\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "177\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ https://t.co/OFppgUN3XK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "178\n",
      "-----\n",
      "New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer https://t.co/41pUGEvmeG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "179\n",
      "-----\n",
      "For the first time, a blood test helped doctors find and treat cancers in seemingly healthy people https://t.co/iR9ZLFJNTj via @sheridan_kate #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "180\n",
      "-----\n",
      "COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "181\n",
      "-----\n",
      "We continue to learn about impact of #COVID19 on #cancer patients. A number of studies reported at @AACR today continue to expand our knowledge. Now we need a coherent picture. What is clear: many patients with #cancer develop serious illness because of their disease/treatment\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "182\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "183\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "184\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "185\n",
      "-----\n",
      "#AACR20 starts as a virtual meeting with 54,000 ppl\n",
      "\n",
      "An important meeting held in this format:\n",
      "Should others follow?\n",
      "\n",
      "üëâNo facility/flight expenses\n",
      "üëâReduced environment impact\n",
      "üëâReduce $ to register\n",
      "üëâMore can participate globally\n",
      "üëâMore important information disseminated https://t.co/OPSjKPNWsG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "186\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "187\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "188\n",
      "-----\n",
      "#Cancer | Uso de #olaparib para c√°ncer de pr√≥stata metast√°sico resistente a castraci√≥n.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "189\n",
      "-----\n",
      "Check out this video by the amazing Dr. @CharuAggarwalMD. \n",
      "\n",
      "#OncoAlert \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "190\n",
      "-----\n",
      "#Metabolism (Oncometabolites) and #DDR as targets to treat #cancer . #AACR20 #OncoAlert https://t.co/58jvSF5Skd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "191\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert üö®are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2‚É£.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "192\n",
      "-----\n",
      "#AACR20 plenary on #PARP‚õîÔ∏è‚ûï#immunotherapy resulted in not only ‚¨ÜÔ∏èpathCR (pCR) but also another important measure: residual cancer burden (RCB). \n",
      "‚úÖHER2‚ûñ20%‚û°Ô∏è37%\n",
      "‚úÖHR‚ûñHER2‚ûñ27%‚û°Ô∏è47%\n",
      "‚úÖHR‚ûïHER2‚ûñ14%‚û°Ô∏è28%\n",
      "#OncoAlert https://t.co/DraYXx4vwL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "193\n",
      "-----\n",
      "Syndax announces positive preclinical profile and initial phase 1 data for the Menin inhibitor SNDX-5613 in adults with relapsed or refractory acute leukemias. #leukemia #AACR20 https://t.co/h4f8uYnZUE https://t.co/g51o4AXVUq\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "194\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "195\n",
      "-----\n",
      "New prospective data on outcomes with IO for NSCLC based on STK11 and KEAP1 status. Certainly limitations with only subset with available NGS results. Some of my best IO responders have been 2 STK11-mut patients. Not ready to skip IO for these patients yet. #AACR20 #LCSM https://t.co/1T8Mwt9hTu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "196\n",
      "-----\n",
      "Are all viruses bad? @Mark_Cobbold, a scientist &amp; VP Oncology Early Discovery, breaks down one of the most exciting areas of cancer research: viruses that are designed to infect and kill cancer cells. #SciencefromAtoZ #AACR20 https://t.co/Q2Iix6vk6y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "197\n",
      "-----\n",
      "The latest The „ÅÆ„Åû„Åø„ÅÆ‰ºö Daily! https://t.co/D5S09IzSL5 Thanks to @cocoha9608 @outsidervoice @cancer_navi #‰π≥„Åå„Çì #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "198\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "199\n",
      "-----\n",
      "TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "200\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "201\n",
      "-----\n",
      "üì¢ Pr Fabrice @barlesi @GustaveRoussy a pr√©sent√© en pl√©ni√®re #Covid19etCancer du congr√®s #AACR20 une analyse pr√©coce de la situation et la mani√®re dont Gustave Roussy s‚Äôest adapt√© avec agilit√© pour g√©rer l‚Äô√©pid√©mie de #covid19.\n",
      "\n",
      "Lire le communiqu√© : https://t.co/VPFdDJgHol\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "202\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "203\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "204\n",
      "-----\n",
      "A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "205\n",
      "-----\n",
      "Clinical activity of TAK-788 - 160 mg qd recommended dose for Phase II #AACR20 https://t.co/BbjUFD1vJD\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "206\n",
      "-----\n",
      "Read @TrendsinPharma \"The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers\" by Muranen (@tarumurmur) and colleagues - https://t.co/SoHGL2ngoO - #CellPressOncology #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "207\n",
      "-----\n",
      "#COVID19 | Un dato bastante e importante  que comparte @LizCancerHealth, en la √°rea #NYC parece existir un √≠ndice de mortalidad m√°s alto en #latinos y #afroamericanos que cauc√°sicos y asi√°ticos, #QuedateEnCasa\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "208\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "209\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "210\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "211\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "212\n",
      "-----\n",
      "First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "213\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "214\n",
      "-----\n",
      "‚ÄúThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,‚Äù says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "215\n",
      "-----\n",
      "Combining the immunotherapy drug durvalumab with chemotherapy achieved improved response in advanced #ovariancancer patients, according to a recent MD Anderson-led study, presented at #AACR20 by our @ShannonWestin:  https://t.co/NXUYjKX0oE #CancerMoonshot #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "216\n",
      "-----\n",
      "#Cancer #COVID19 | @chulkimMD comparte algunos puntos importantes a considerar sobre el #Cancer a partir de la pandemia de la autor√≠a del Dr. Louis Voight\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "217\n",
      "-----\n",
      "Cancer patients like triple-negative #breastcancer survivor @deb_silverman are among those most vulnerable to #COVID19: https://t.co/4M0pycC7i1 @washingtonpost #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "218\n",
      "-----\n",
      "‚ÄúThese variations highlight the need for continued study of #brainmetastases in order to better understand them and potentially find therapeutic targets,‚Äù says our Dr. Andy Futreal: https://t.co/0qEDHCjyUS #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "219\n",
      "-----\n",
      "The Phase III EMBRACA clinical trial led by our @JenniferLitton showed advanced #breastcancer patients taking talazoparib had better overall health for longer than those on chemotherapy: https://t.co/BdTotwoukm #AACR20 #bcsm #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "220\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "221\n",
      "-----\n",
      "#Covid19 and #Cancer lecture in #AACR20 . #OncoAlert\n",
      "‚úÖNo anti-cancer treatment associated with higher mortality\n",
      "‚úÖPatients treateted with ICI wer NOT more succeptible to infection\n",
      "‚úÖpatchy consolidation risk factor for severe events\n",
      "‚úÖdon¬¥t forget cancer tx. https://t.co/zVXpumDKIv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "222\n",
      "-----\n",
      "#Cancer #COVID19 | Algunos puntos impotentes a considerar del #AACR20 sobre el manejo oncol√≥gico durante #COVID__19\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "223\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "224\n",
      "-----\n",
      "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention @ScienceMagazine  #AACR20 #cancerscreening https://t.co/fWAVjO6TUB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "225\n",
      "-----\n",
      "DNA blood test spots cancers in seemingly cancer-free women, but also produces false alarms #AACR20 #cancerscreening https://t.co/1SOMVbRPU4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "226\n",
      "-----\n",
      "#COVID19 | Hoy m√°s que nunca es crucial compartir nuestra informaci√≥n con la comunidad m√©dica y el trato cercano con nuestros pacientes. #Cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "227\n",
      "-----\n",
      "‚ÄúOur preclinical data suggest that IPN60090 may be effective in underserved groups of patients who need better treatment options,‚Äù says our Dr. Jeffrey Kovacs: https://t.co/nAcAdjEdXQ #AACR20 #CancerMoonshot #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "228\n",
      "-----\n",
      "Our phase II study of combination of durvalumab and standard chemotherapy in #ovariancancer will be presented today at the virtual #AACR20 meeting!  #gyncsm #CancerMoonshot #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "229\n",
      "-----\n",
      "Some of the outstanding questions in #ctDNA #AACR20 by Dr Huntsman @UBC - longitudinal impact, sensitivity, financial burden, and of course some of the advantages arising under the lens of #COVID19 https://t.co/kLg08Cuvce\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "230\n",
      "-----\n",
      "Detecting cancer early matters. Kudos to the team at Thrive and @MichaelPellini  for their prospective trial showing that a series of blood tests with low false positive rates can safely enable earlier detection of multiple cancers. Congrats! #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "231\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "232\n",
      "-----\n",
      "Blood Test Is Feasible for Early Detection Across Multiple Cancers @HopkinsMedicine @AACR #AACR20 https://t.co/4N1346mbwQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "233\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB https://t.co/V35FL0gi6u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "234\n",
      "-----\n",
      "DNA blood test spots cancers in seemingly cancer-free women, but also produces false alarms #AACR20 #cancerscreening https://t.co/1SOMVbRPU4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "235\n",
      "-----\n",
      "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention @ScienceMagazine  #AACR20 #cancerscreening https://t.co/fWAVjO6TUB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "236\n",
      "-----\n",
      "@MethodistHosp @sloan_kettering @MountSinaiNYC @DanaFarber @KimmelCancerCtr https://t.co/Fthgoi57Io\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "237\n",
      "-----\n",
      "These are great numbers @AACR - and so are the blockbuster number of residents. Great planning in short order to make #AACR20 virtual.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "238\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "239\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "240\n",
      "-----\n",
      "The results of our Naproxen in #LynchSyndrome Phase I clinical trial presented today at #AACR20 @AACR Naproxen induced activation of resident immune cells in the normal colorectal mucosa #immuneinterception üëá\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "241\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB https://t.co/V35FL0gi6u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "242\n",
      "-----\n",
      "One more time for the folks in the back‚Äî #WordsMatter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "243\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here‚Äôs a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "244\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "245\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "246\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "247\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "248\n",
      "-----\n",
      "Excited to have @BrendonStilesMD with us tmrw as we continue our discussions on management of #LungCancer during #COVID19, including updates from #AACR20 \n",
      "@StephenVLiu @JackWestMD @n8pennell @OncLive @ginacolumbusonc #LCSM @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "249\n",
      "-----\n",
      "Presentan resultados de ensayo cl√≠nico CIMAvax en congreso de Asociaci√≥n para la Investigaci√≥n del C√°ncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "250\n",
      "-----\n",
      "Blood Test Is Feasible for Early Detection Across Multiple Cancers @HopkinsMedicine @AACR #AACR20 https://t.co/4N1346mbwQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "251\n",
      "-----\n",
      "COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "252\n",
      "-----\n",
      "TIL Therapy Elicits Encouraging Activity in Advanced NSCLC @MoffittNews @AACR #lcsm #AACR20 https://t.co/qxwMwtrTrR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "253\n",
      "-----\n",
      "Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL @DanaFarber @AACR #lymsm #AACR20 https://t.co/sZhSb8dbdB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "254\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "255\n",
      "-----\n",
      "Adopting Multidisciplinary and Evolving Care Plans Are Essential to Treat Cancer and COVID-19 @Hospital12deOct @AACR #COVID19 #coronavirus #AACR20 https://t.co/8ZAKK5KC40\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "256\n",
      "-----\n",
      "Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19 @barlesi @GustaveRoussy @AACR #coronavirus #COVID19 #AACR20 https://t.co/FDtUuutt8w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "257\n",
      "-----\n",
      "Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL @NCIResearchCtr @AACR #AACR20 #leusm https://t.co/9i0ji0YNCf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "258\n",
      "-----\n",
      "Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC @JohnWayneCI @SaintJohns2 @AACR #bcsm #AACR20 https://t.co/cdaVe8HCdV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "259\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies. https://t.co/MabdIDGsFI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "260\n",
      "-----\n",
      "This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "261\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "262\n",
      "-----\n",
      "#AACR20 Here is the link to the paper published in Annals of Oncology by Zhang et al on the clinical characteristics of patients with cancer infected by #COVID19 https://t.co/qSrRxJLMvY https://t.co/STAKx1RkSR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "263\n",
      "-----\n",
      "I‚Äôm with Joshua. This pathologic obsession with secrecy in medical conferences is so 20th century.\n",
      "\n",
      "Isn‚Äôt the goal to make great medical breakthroughs and other key medical information freely available to everyone as quickly as possible using all available technology?\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "264\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "‚¨ÜÔ∏è pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "265\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "266\n",
      "-----\n",
      "TIL Therapy Elicits Encouraging Activity in Advanced NSCLC https://t.co/7xPmSfSQZA #AACR20 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "267\n",
      "-----\n",
      "FDA Grants Mobocertinib (TAK-788) Breakthrough Designation for EGFR Exon 20-Mutant NSCLC https://t.co/VbM00DvgxX #AACR20 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "268\n",
      "-----\n",
      "Check recent content @NatureCancer\n",
      " about #ctDNA and #LiquidBiopsy in cancer:\n",
      "\n",
      "- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!\n",
      "\n",
      "https://t.co/OMPFaRGU65\n",
      "https://t.co/SXvHYm5Hmw\n",
      "https://t.co/e26wYMedBV\n",
      "https://t.co/CErTHIOYvA\n",
      "\n",
      "#AACR20 https://t.co/agOl6k5Zfh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "269\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "270\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "271\n",
      "-----\n",
      "Journal of Cancer Science and Research#Submitmanuscript#COVID-19\n",
      "https://t.co/f5JF352O5r\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "272\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "273\n",
      "-----\n",
      "Wau lots of fluorine any F polar interactions described? Or ‚Äûonly‚Äú metabolic stability? Looks exciting\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "274\n",
      "-----\n",
      "CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richter‚Äôs transformation is ongoing #lymsm https://t.co/aJwPboXCDS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "275\n",
      "-----\n",
      "CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richter‚Äôs transformation is ongoing #lymsm https://t.co/aJwPboXCDS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "276\n",
      "-----\n",
      "Today's Health Conferences: #AACR20 #depression #aacr2020 https://t.co/YnZewsLKhm #hcsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "277\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "278\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "279\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "280\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "281\n",
      "-----\n",
      "WATCH: Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS @WeillCornell @nyphospital @AACR #AACR20 https://t.co/onAWDHZzuu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "282\n",
      "-----\n",
      "I‚Äôm with Joshua. This pathologic obsession with secrecy in medical conferences is so 20th century.\n",
      "\n",
      "Isn‚Äôt the goal to make great medical breakthroughs and other key medical information freely available to everyone as quickly as possible using all available technology?\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "283\n",
      "-----\n",
      "üì¢ Pr Fabrice @barlesi @GustaveRoussy a pr√©sent√© en pl√©ni√®re #Covid19etCancer du congr√®s #AACR20 une analyse pr√©coce de la situation et la mani√®re dont Gustave Roussy s‚Äôest adapt√© avec agilit√© pour g√©rer l‚Äô√©pid√©mie de #covid19.\n",
      "\n",
      "Lire le communiqu√© : https://t.co/VPFdDJgHol\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "284\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "285\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "286\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies. https://t.co/MabdIDGsFI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "287\n",
      "-----\n",
      "#AACR20 news: No improvement in metastatic #CRPC outcomes with addition of #atezolizumab to #enzalutamide - phase 3 IMbassador250 data reported by @ChrisSweens1 (of @DanaFarber) #immunotherapy @PCF_Science @DanaFarberNews @uroupdate https://t.co/APLniIkJyC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "288\n",
      "-----\n",
      "#AACR20 news: No improvement in metastatic #CRPC outcomes with addition of #atezolizumab to #enzalutamide - phase 3 IMbassador250 data reported by @ChrisSweens1 (of @DanaFarber) #immunotherapy @PCF_Science @DanaFarberNews @uroupdate https://t.co/APLniIkJyC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "289\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "290\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "291\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "292\n",
      "-----\n",
      "Dr Marina Garassino @marinagarassino presenting data from #TERAVOLT evaluating #COVID19 and lung cancer #LCSM \n",
      "Results overlapping with our own institutional experience recently spread via #SoMe #AACR20 @AACR @OncoAlert #OncoAlert @IASLC @gecp_org https://t.co/zcglqIyYow\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "293\n",
      "-----\n",
      "#AACR20 #LCSM #EGFR\n",
      "Disappointing results of #Poziotinib in 2L+ EGFR Exon20ins (n=115) by @LeXiuning\n",
      "ORR: 15% | mPFS: 4.2 m \n",
      "TRAEs ‚â• 3: 63% (72/114) w/ 68% dose-reduction!\n",
      "Toxic profile w/ limited activity for being a good TKI. \n",
      "What to expect from Ph3? Not much else \n",
      "#OncoAlert https://t.co/ihvbaL7gZU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "294\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "295\n",
      "-----\n",
      "This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "296\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "297\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "298\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here‚Äôs a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "299\n",
      "-----\n",
      "Coinciding with the #COVID19nCancer session at #AACR20, @CD_AACR has published the largest peer reviewed series (thus far) of #COVID19 in cancer patients (N=105 from China). \n",
      "Overall, a higher rate of complications is seen across the board. @tmprowell \n",
      "https://t.co/sgH7lEi0z6 https://t.co/32VGCKwx2u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "300\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "301\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "302\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "303\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "304\n",
      "-----\n",
      "A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "305\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "306\n",
      "-----\n",
      "This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "307\n",
      "-----\n",
      "Toxicity of capmatinib is generally pretty mild, and not dissimilar from with crizotinib.  We gain CNS efficacy without cost in the form of toxicity.  Hopefully patients will have access to this agent soon. It is currently under priority review at the FDA #AACR20 #LCSM https://t.co/s4f8Gble9o\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "308\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "309\n",
      "-----\n",
      "What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the world‚Äôs largest webinar (can‚Äôt wait to see demographic data);\n",
      "2. KRAS is Undrugged (*yet*), not Undruggable;\n",
      "3. BRAF is the ultimate Hydra;           4. @AACR really came throughüëç\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "310\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "311\n",
      "-----\n",
      "@OncoAlert @BenWestphalen @weoncologists #AACR20 üëÜüèº#BRAF - one of my patients recently sent me this illustrating from a recent review the diversity of tumor types in which #BRAF mutations are seen as well as the spectrum of mutations (V600E üÜö non-V600E); classifications of #BRAF mutations. #precisionmedicine https://t.co/Ls3p52ijEs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "312\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "313\n",
      "-----\n",
      "Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection https://t.co/xDeTQGB7yH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "314\n",
      "-----\n",
      "Next \"new drug on the horizon\" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.\n",
      "\n",
      "Currently recruiting patients with #ER+ #MBC. \n",
      "\n",
      "#BCSM #AACR20 \n",
      "https://t.co/7aWgt2Bv60\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "315\n",
      "-----\n",
      "Thread by @ADesaiMD: Missed #COVID19nCancer plenary in #AACR20 @AACR? Here‚Äôs a thread to catch up on all the fascinating global research presy: @AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@Onco‚Ä¶ https://t.co/jiRO4nRWCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "316\n",
      "-----\n",
      "Ê≠¶Êº¢„Åã„Çâ„ÅÆÂ§öÊñΩË®≠Âæå„ÇçÂêë„ÅçÁ†îÁ©∂„ÄÇ\n",
      "‚òëÔ∏è„Åå„ÇìÊÇ£ËÄÖ„ÅØÊ≠ª‰∫°„ÇíÂê´„ÇÅ„ÅüÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èË°ÄÊ∂≤ËÖ´Áòç„Å®ËÇ∫Áôå„ÄÅÁóÖÊúüStageIV„ÅÆ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èÊ≤ªÁôÇÊ≥ï„Åß„ÅØ„ÄÅÊâãË°ì„ÇÑÂÖçÁñ´„ÉÅ„Çß„ÉÉ„ÇØ„Éù„Ç§„É≥„ÉàÈòªÂÆ≥Ëñ¨„ÅØÊúâÊÑè„Å´ÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÅÆÊúâÁÑ°„Åß„ÅØÊúâÊÑèÂ∑Æ„Å™„Åó„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "317\n",
      "-----\n",
      "Ê≠¶Êº¢„Åã„Çâ„ÅÆÂ§öÊñΩË®≠Âæå„ÇçÂêë„ÅçÁ†îÁ©∂„ÄÇ\n",
      "‚òëÔ∏è„Åå„ÇìÊÇ£ËÄÖ„ÅØÊ≠ª‰∫°„ÇíÂê´„ÇÅ„ÅüÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èË°ÄÊ∂≤ËÖ´Áòç„Å®ËÇ∫Áôå„ÄÅÁóÖÊúüStageIV„ÅÆ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èÊ≤ªÁôÇÊ≥ï„Åß„ÅØ„ÄÅÊâãË°ì„ÇÑÂÖçÁñ´„ÉÅ„Çß„ÉÉ„ÇØ„Éù„Ç§„É≥„ÉàÈòªÂÆ≥Ëñ¨„ÅØÊúâÊÑè„Å´ÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÅÆÊúâÁÑ°„Åß„ÅØÊúâÊÑèÂ∑Æ„Å™„Åó„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "318\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "319\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "320\n",
      "-----\n",
      "This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "321\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "322\n",
      "-----\n",
      "Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "323\n",
      "-----\n",
      "Pre existing ESR1 mutations in early stage primary breast cancer predict failure of endocrine therapy and poor OS. This is important and should guide how we think about ER+ breast cancer. #aacr20 https://t.co/DC3ROEJt4l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "324\n",
      "-----\n",
      "Check recent content @NatureCancer\n",
      " about #ctDNA and #LiquidBiopsy in cancer:\n",
      "\n",
      "- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!\n",
      "\n",
      "https://t.co/OMPFaRGU65\n",
      "https://t.co/SXvHYm5Hmw\n",
      "https://t.co/e26wYMedBV\n",
      "https://t.co/CErTHIOYvA\n",
      "\n",
      "#AACR20 https://t.co/agOl6k5Zfh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "325\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "326\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "327\n",
      "-----\n",
      "Check recent content @NatureCancer about #ctDNA and #LiquidBiopsy in cancer:\n",
      "\n",
      "- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!\n",
      "\n",
      "https://t.co/BSc74nrBFa\n",
      "https://t.co/0TgSQO7k9Y\n",
      "https://t.co/KIxFN8Gu2k\n",
      "https://t.co/HZlrrXXsN3\n",
      "\n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "328\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "329\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "330\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "331\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "332\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "333\n",
      "-----\n",
      "#AlligatorBioscience Presents Promising Interim Phase I Data for its #BispecificDrugCandidate #ATOR1015 at #AACR20 $ATORX https://t.co/HZuJw1DQGY\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "334\n",
      "-----\n",
      "Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer https://t.co/m4Dr6kU662\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "335\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "336\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "337\n",
      "-----\n",
      "Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "338\n",
      "-----\n",
      "Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection https://t.co/xDeTQGB7yH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "339\n",
      "-----\n",
      "Great chairing from Dr Fertig @FertigLab &amp; Dr Turajlic @SamraTurajlic at \"Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease\" #AACR20 Virtual #science MinisympüôèThanks @AACR for all efforts making this possible in challenging times! #StaySafe\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "340\n",
      "-----\n",
      "Nuovi dati su #Vitrakvi e highlights sul nuovo AhR-inibitore presentati da @Bayer durante #AACR20.\n",
      "La nostra #ricerca in #oncologia non si ferma. \n",
      "Trovare #nuovesoluzioni √© la nostra mission.\n",
      "#scienceforabetterlife il nostro motto.\n",
      "#StrongerTogether\n",
      "\n",
      "https://t.co/vCE8rIqBa7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "341\n",
      "-----\n",
      "I dream of a day when academicians will understand we don‚Äôt know how to prevent lung cancer. We only know how to reduce risk in people who smoke. #lcsm #radonc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "342\n",
      "-----\n",
      "#AACR20: Iovance revels in promising lung cancer data out of Moffitt as TIL therapy triggers 2 complete responses https://t.co/cIi0bl2sLf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "343\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "344\n",
      "-----\n",
      "Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "345\n",
      "-----\n",
      "#OncoAlert #AACR20 Dr. Carlos Gomez-Martin presents #COVID19 data from Hospital 12 de Octubre in Madrid, Spain. Data slides not posted at his request but of note: higher proportion of patients with lung cancer, mortality 25%, radiographic changes common, neutropenia a major risk. https://t.co/s9JOTPgEur\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "346\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "347\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "348\n",
      "-----\n",
      "#AACR20 thanks for sharing this slide. #immunotherapy usage #COVID19 #COVID19 @jsoriamd @GustaveRoussy @barlesi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "349\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "350\n",
      "-----\n",
      "#AACR20 more on PARP‚õîÔ∏è #BRCA #DNA-Repair üß¨\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "351\n",
      "-----\n",
      "#Metabolism (Oncometabolites) and #DDR as targets to treat #cancer . #AACR20 #OncoAlert https://t.co/58jvSF5Skd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "352\n",
      "-----\n",
      "#AACR20: Early data suggest #Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions https://t.co/UR3ZCbxWX9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "353\n",
      "-----\n",
      "#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse pr√©coce de la mani√®re dont ce #CLCC s‚Äôest adapt√© pour g√©rer l‚Äô√©pid√©mie #COVID19\n",
      "@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "354\n",
      "-----\n",
      "Capmatinib continues to show promise fr Met Exon 14 skipping NSCLC, including brain mets. Reinforces need for comprehensive biomarker testing to catch these rare mutations so our patients can benefit from these new drugs - LUNGevity SAB Dr. Eddie Garron @UCLAJCCC #AACR20 #LCSM https://t.co/s5GBmIMq3x\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "355\n",
      "-----\n",
      "The latest The Thi·∫øt k·∫ø bi·ªát th·ª± ƒë·∫πp Kh√¥ng Gian Vi·ªát ! https://t.co/SmaQSV5Ic8 Thanks to @mndp023 @phoenixemk @Dr_ZiMingZhao #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "356\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 cancer patients have a 15% mortality . Is this good outcome notably related to the almost 10% of patients who received compassionate #Tocilizumab ? \n",
      "https://t.co/dRmW2rAHaG https://t.co/1kc0iD9VcV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "357\n",
      "-----\n",
      "This slide was presented in the Lung Cancer Targeted Therapies session at #AACR20 today. As a healthy 47 year old when dx with stage IV #lungcancer completely out of the blue, with no known risk factors, I would like to know how I could have PREVENTED my LC #lcsm @AACRFoundation https://t.co/VIGVdFoHtB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "358\n",
      "-----\n",
      "What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the world‚Äôs largest webinar (can‚Äôt wait to see demographic data);\n",
      "2. KRAS is Undrugged (*yet*), not Undruggable;\n",
      "3. BRAF is the ultimate Hydra;           4. @AACR really came throughüëç\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "359\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "360\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "361\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "362\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "363\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "364\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "365\n",
      "-----\n",
      "Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "366\n",
      "-----\n",
      "These are great numbers @AACR - and so are the blockbuster number of residents. Great planning in short order to make #AACR20 virtual.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "367\n",
      "-----\n",
      "We‚Äôre focused on genomic #cancer testing. These tests may help doctors recommend treatments and clinical trials based on a patient‚Äôs unique tumor makeup. Learn about the importance of genomic cancer testing today: https://t.co/JJ2xbWEDR4 #AACR20 https://t.co/ZLuvR1cAE9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "368\n",
      "-----\n",
      "üó£Ô∏è What was your lymphoma highlight from Day 1 of #AACR20? Vote below, or let us know in the comments!  ‚¨áÔ∏è#lymsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "369\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "370\n",
      "-----\n",
      "Have your say üó£Ô∏è What was your AML highlight from Day 1 at #AACR20? #leusm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "371\n",
      "-----\n",
      "Metabolomic adaptations and correlates of survival to immune checkpoint blockade: https://t.co/bGMKiJQ75L\n",
      "\n",
      "#AACR20 #biomarkers https://t.co/GFaoBgO9kx\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "372\n",
      "-----\n",
      "Excited to have @BrendonStilesMD with us tmrw as we continue our discussions on management of #LungCancer during #COVID19, including updates from #AACR20 \n",
      "@StephenVLiu @JackWestMD @n8pennell @OncLive @ginacolumbusonc #LCSM @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "373\n",
      "-----\n",
      "Find out what the Editors of @OncologyCentral, @MyBioTechniques and @NanomedZone thought of day 1 #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "374\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "375\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "376\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "377\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "378\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "379\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "380\n",
      "-----\n",
      "Just outüì£at @TheLancetOncol üì∞by @OncoAlert üö®colleague @FAndreMD &amp;team. MonarcHER sees combo abemaciclib,fulvestrant, &amp;trastuzumab improved PFS Vs. SOC #chemotherapy +trastuzumab, w/a tolerable safety‚ÄºÔ∏è#breastcancer #aacr20 #bcsm https://t.co/ZLtdVsul0O https://t.co/gi8FMoJcrv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "381\n",
      "-----\n",
      "Thank you @AACR for a great first day of this Amazing #AACR20 , very very well done &amp; we are grateful for all your hard work‚ÄºÔ∏èHere are some of the logistics from our friends at @symplur for today\n",
      "Best,\n",
      "@OncoAlert üö®\n",
      "https://t.co/pGGYMfhVyP https://t.co/XZqjgjkCGv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "382\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "383\n",
      "-----\n",
      "An amazing job with this Virtual #AACR20 , Kudos‚ÄºÔ∏è  \n",
      "Thank you very much to all the hard working people at @AACR for making this possible‚ÄºÔ∏èWay to set the barüôå\n",
      "Best from @weoncologists &amp; all of us at @OncoAlert üö® https://t.co/R5MDUSCIQ9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "384\n",
      "-----\n",
      "Dear friends,\n",
      "Quick Poll on which part of the worldüåèour Colleagues (Doctors, Nurses, Scientists &amp; Patient Advocates) attending #AACR20 are coming from, care to share?\n",
      "best,\n",
      "@weoncologists &amp; @OncoAlert üö®\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "385\n",
      "-----\n",
      "Thank you @AACR , an Amazing Part 1‚É£of  #AACR20 and thank you for making registration free‚ÄºÔ∏èSuch details eliminates the economic issues many colleagues face in their countries &amp; makes it available to ALL, VERY well done‚ÄºÔ∏è\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "386\n",
      "-----\n",
      "Live #AACR20 Study from @MDAndersonNews Shows how Taking Naproxenüíädaily may reduce the risk of developing #Colorectalcancer in people with #lynchSyndrome @OncoAlert üö®#CRC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "387\n",
      "-----\n",
      "Our @OncoAlert üö®colleague @ErikaHamilton9 üë©‚Äç‚öïÔ∏èof @SarahCannonDocs Live from #AACR20 discussing the I-SPY2 trial by @YaleCancer .Addition of durvalumab &amp; olaparib to neoadjuvant paclitaxel improved pCR in high-risk, HER2- stage II/III #breastcancer #BCSM\n",
      "Edit: @weoncologists https://t.co/OWj0UnnxIh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "388\n",
      "-----\n",
      "Our @OncoAlert üö®colleague @itsnot_pink live from #AACR20 discussing EMBRACA trial led by @MDAndersonNews .Advanced #breastcancer patients w/ #BRCA mutation, talazoparib did not see improved OS compared to #chemotherapy \n",
      "However did see improved QOL‚ÄºÔ∏è#BCSM\n",
      "edited: @weoncologists https://t.co/9aMaP9tnXK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "389\n",
      "-----\n",
      "Coming up in üîüminutes, part 2Ô∏è‚É£of #AACR20 And @OncoAlert üö®will be there #OncoAlert üåé https://t.co/DTt6Jjr0I7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "390\n",
      "-----\n",
      "Up next at #AACR20 our @OncoAlert üö®colleague @marinagarassino üë©‚Äç‚öïÔ∏èto present #TERAVOLT A testament of how the #lungcancer come come@together and unite‚ÄºÔ∏è@peters_solange @barlesi @EnriquetaFelip @IASLC @HwakeleeMD\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "391\n",
      "-----\n",
      "Our @OncoAlert üö®colleague @BenWestphalen üßë‚Äç‚öïÔ∏èfrom University of Munich on the #AACR20 GENIE project. Focus on Abstract 1092 on #BRAF mutations üß¨\n",
      "Edited: @weoncologists https://t.co/sB0bII8C8G\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "392\n",
      "-----\n",
      "First results from #TERAVOLT are out and presented today at #AACR20 by our @myESMO @OncoAlert üö®colleague @marinagarassino üë©‚Äç‚öïÔ∏èshowing high mortality rate of #COVID19 in patients with thoracic malignancies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "393\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @LeciaSequist üë©‚Äç‚öïÔ∏èof @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer \n",
      "Edited: @weoncologists https://t.co/U9ZPHynuZA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "394\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "395\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "396\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "397\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "398\n",
      "-----\n",
      "First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "399\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @CharuAggarwalMD üë©‚Äç‚öïÔ∏èfrom @PennCancer  Virtually Live at #AACR20 discussing globalüåèpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino üáÆüáπ&amp; The French experience by @barlesi from @GustaveRoussy üá´üá∑\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "400\n",
      "-----\n",
      "Here‚Äôs what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "401\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert üö®Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‚ÄºÔ∏è https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "402\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert üö®are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2‚É£.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "403\n",
      "-----\n",
      "#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse pr√©coce de la mani√®re dont ce #CLCC s‚Äôest adapt√© pour g√©rer l‚Äô√©pid√©mie #COVID19\n",
      "@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "404\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert üö®are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2‚É£.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "405\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "406\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland. https://t.co/pnODKXsAPW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "407\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "408\n",
      "-----\n",
      "Can we predict which cancer patients will respond to #immunotherapy? Predictive biomarkers are currently being discussed at a minisymposium at the #AACR20 Virtual Annual Meeting. https://t.co/095y0qDmAn\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "409\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "410\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "411\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "412\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "413\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "414\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "415\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "416\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "417\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "418\n",
      "-----\n",
      "Facing previous data suggesting imunorresistance, this small exploratory analysis of KN042 exhibits IO monotherapy benefit for PDL1 &gt; 1% patients regardless of STK11/KEAP1 status. Nevertheless it seems insufficient to encourage mono IO as 1L for STK11/KEAP1 mut NSCLC. #AACR20 https://t.co/QviVJqAId1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "419\n",
      "-----\n",
      "Today‚Äôs @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "420\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "421\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "422\n",
      "-----\n",
      "Results were presented today during the Early Detection and ctDNA Clinical Plenary Session on the second day of #AACR20 Virtual Annual Meeting I.\n",
      "https://t.co/4uEHUe1Hpn\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "423\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "424\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. David D. Thiel presents results from a study that tested a multicancer early detection liquid biopsy test designed to predict the presence or absence of cancer and the tissue of origin. https://t.co/v8y6FZvGOS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "425\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Ben Creelan presents results from a phase I trial. Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC). https://t.co/CzRhFEQL6I\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "426\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Xinxin Wang presents: Clinical safety and efficacy study of TruUCAR‚Ñ¢ GC027: The first-in-human, universal CAR T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). https://t.co/NMcFSXBDzG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "427\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Haneen Shalabi presents findings on the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "428\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "429\n",
      "-----\n",
      "Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "430\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "431\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "432\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "433\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "434\n",
      "-----\n",
      "The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "435\n",
      "-----\n",
      "üì¢ Pr Fabrice @barlesi @GustaveRoussy a pr√©sent√© en pl√©ni√®re #Covid19etCancer du congr√®s #AACR20 une analyse pr√©coce de la situation et la mani√®re dont Gustave Roussy s‚Äôest adapt√© avec agilit√© pour g√©rer l‚Äô√©pid√©mie de #covid19.\n",
      "\n",
      "Lire le communiqu√© : https://t.co/VPFdDJgHol\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "436\n",
      "-----\n",
      "We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "437\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "438\n",
      "-----\n",
      "The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "439\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "440\n",
      "-----\n",
      "Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "441\n",
      "-----\n",
      "The latest EIPG Pharma #ICYMI! https://t.co/ffTGNh75sh #pharma #pharmaceutical #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "442\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "443\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "444\n",
      "-----\n",
      "TERAVOLT Data Reveal \"Unexpectedly High\" Mortality in Patients With Thoracic Cancers and COVID-19 @IstTumori @AACR #COVID19 #coronavirus #AACR20 https://t.co/x8z3rAw5dS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "445\n",
      "-----\n",
      "COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "446\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "447\n",
      "-----\n",
      "TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "448\n",
      "-----\n",
      "‚ö°Ô∏è Highlights from the @AACR Annual Meeting 2020 in lymphoma are now available in this @lymphomahub Twitter Moment ‚ñ∂Ô∏è https://t.co/1P9IBcn29K ‚óÄÔ∏è #lymsm #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "449\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "450\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "451\n",
      "-----\n",
      "‚ö°Ô∏è If you missed the @AACR meeting, click below to view a Twitter Moment created by the @AML_Hub, providing you with the latest updates in #AML from the meeting: https://t.co/KgiY9MSrYR #leusm #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "452\n",
      "-----\n",
      "$VSTM CKI27 + defactinib in Kras mutant cancers, via Udai Banerji. Note responses in subjects on prior Mek inhibitor treatment #AACR20 https://t.co/agkGzF2ZWb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "453\n",
      "-----\n",
      "$VSTM shows promise in Kras-mutated cancers at #AACR20, so why is it off 40%? Via @evaluatevantage https://t.co/oefEHadoNi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "454\n",
      "-----\n",
      "We‚Äôre focused on genomic #cancer testing. These tests may help doctors recommend treatments and clinical trials based on a patient‚Äôs unique tumor makeup. Learn about the importance of genomic cancer testing today: https://t.co/JJ2xbWEDR4 #AACR20 https://t.co/ZLuvR1cAE9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "455\n",
      "-----\n",
      "@Aiims1742 üëáüèºInteresting to note that while the discussion/data at #AACR20 showed a higher HR for #cancer &amp; #COVID19, (almost ~3), it‚Äôs very likely that this potentially may be driven to some extent by other chronic conditions &amp; advanced age. #COVID19nCancer listed as ‚Äòmalignant neoplasm‚Äô. https://t.co/BPwVl3gQBM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "456\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "457\n",
      "-----\n",
      "@Aiims1742 üëáüèºInteresting to note that while the discussion/data at #AACR20 showed a higher HR for #cancer &amp; #COVID19, (almost ~3), it‚Äôs very likely that this potentially may be driven to some extent by other chronic conditions &amp; advanced age. #COVID19nCancer listed as ‚Äòmalignant neoplasm‚Äô. https://t.co/BPwVl3gQBM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "458\n",
      "-----\n",
      "Delighted to be part of the @ICR_DDU_IIT team running 3 phaseI trials, results of which have been presented at #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "459\n",
      "-----\n",
      "‚ö°Ô∏è Highlights from the @AACR Annual Meeting 2020 in lymphoma are now available in this @lymphomahub Twitter Moment ‚ñ∂Ô∏è https://t.co/1P9IBcn29K ‚óÄÔ∏è #lymsm #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "460\n",
      "-----\n",
      "‚ö°Ô∏è If you missed the @AACR meeting, click below to view a Twitter Moment created by the @AML_Hub, providing you with the latest updates in #AML from the meeting: https://t.co/KgiY9MSrYR #leusm #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "461\n",
      "-----\n",
      "Delighted to be part of the @ICR_DDU_IIT @royalmarsdenNHS running three phase 1 trials, results of which were presented at #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "462\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "463\n",
      "-----\n",
      "Check out this video by the amazing Dr. @CharuAggarwalMD. \n",
      "\n",
      "#OncoAlert \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "464\n",
      "-----\n",
      "Thanks #AACR20 - It has been fantastic, I'm amazed of how such gigantic conference has adapted so quickly to the difficulties! I'm grateful for the new interactions and for the outlook of the field, the cancer research community stands strong! See you again in June! üòç\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "465\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "466\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "467\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "468\n",
      "-----\n",
      "A significant difference between shedders &amp; non shedders in screening, lead time &amp; DFS. Could pre op status of patient ctDNA be a potential biomarker? Stresses tissue biopsy critical if the ctDNA is negative #AACR20 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "469\n",
      "-----\n",
      "Thanks #AACR20 - It has been fantastic, I'm amazed of how such gigantic conference has adapted so quickly to the difficulties! I'm grateful for the new interactions and for the outlook of the field, the cancer research community stands strong! See you again in June! üòç\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "470\n",
      "-----\n",
      "Thanks #AACR2020\n",
      "See you in June for Virtual Annual Meeting II\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "471\n",
      "-----\n",
      "ÂáÑ„Åæ„Åò„ÅÑÁµêÊûú„Å†„Å™„ÄÅ„Åì„Çå\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "472\n",
      "-----\n",
      "#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse pr√©coce de la mani√®re dont ce #CLCC s‚Äôest adapt√© pour g√©rer l‚Äô√©pid√©mie #COVID19\n",
      "@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "473\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "474\n",
      "-----\n",
      "Delighted to be part of the @ICR_DDU_IIT @royalmarsdenNHS running three phase 1 trials, results of which were presented at #AACR20 https://t.co/0AbGAz99OF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "475\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "476\n",
      "-----\n",
      "Top Influencers of #AACR20: @AACR @OncoAlert @weoncologists @Jbauml @marinagarassino @barlesi @tmprowell More üìä https://t.co/RpQ7HRwmN3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "477\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "478\n",
      "-----\n",
      "Top Influencers of #AACR20: @AACR @OncoAlert @weoncologists @Jbauml @marinagarassino @barlesi @tmprowell More üìä https://t.co/RpQ7HRwmN3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "479\n",
      "-----\n",
      "‚ÄúThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,‚Äù says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "480\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "481\n",
      "-----\n",
      "WATCH: Nickolas Papadopoulos, PhD, of @HopkinsMedicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer. @AACR #AACR20 https://t.co/tEgRPfjPSC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "482\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "483\n",
      "-----\n",
      "@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm\n",
      "\n",
      "Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1\n",
      "\n",
      "Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant\n",
      "\n",
      "https://t.co/bLGxRlKKu1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "484\n",
      "-----\n",
      "Read the Clinical Trials collection - newly released for the #AACR20 Virtual Annual Meeting I! https://t.co/TCMvqxZcxC https://t.co/UEmZK1wAGW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "485\n",
      "-----\n",
      "The latest The Cancer News Daily! https://t.co/OfWNStOvgo Thanks to @PennCancer @FDAOncology #ascoconnection #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "486\n",
      "-----\n",
      "STAT story on this Gracell allo data. Definitely one of the more intriguing things we saw at #AACR20. https://t.co/EQJ9wzHiJk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "487\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "488\n",
      "-----\n",
      "For the first time, we‚Äôre disclosing the molecular structure of mobocertinib (TAK-788)! Join us tomorrow during #AACR20‚Äôs virtual annual meeting at 11:14AM EST to learn more.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "489\n",
      "-----\n",
      "$VSTM shows promise in Kras-mutated cancers at #AACR20, so why is it off 40%? Via @evaluatevantage https://t.co/oefEHadoNi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "490\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "491\n",
      "-----\n",
      "Thank you @AACR , an Amazing Part 1‚É£of  #AACR20 and thank you for making registration free‚ÄºÔ∏èSuch details eliminates the economic issues many colleagues face in their countries &amp; makes it available to ALL, VERY well done‚ÄºÔ∏è\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "492\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "493\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "494\n",
      "-----\n",
      "Ê≠¶Êº¢„Åã„Çâ„ÅÆÂ§öÊñΩË®≠Âæå„ÇçÂêë„ÅçÁ†îÁ©∂„ÄÇ\n",
      "‚òëÔ∏è„Åå„ÇìÊÇ£ËÄÖ„ÅØÊ≠ª‰∫°„ÇíÂê´„ÇÅ„ÅüÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èË°ÄÊ∂≤ËÖ´Áòç„Å®ËÇ∫Áôå„ÄÅÁóÖÊúüStageIV„ÅÆ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èÊ≤ªÁôÇÊ≥ï„Åß„ÅØ„ÄÅÊâãË°ì„ÇÑÂÖçÁñ´„ÉÅ„Çß„ÉÉ„ÇØ„Éù„Ç§„É≥„ÉàÈòªÂÆ≥Ëñ¨„ÅØÊúâÊÑè„Å´ÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÅÆÊúâÁÑ°„Åß„ÅØÊúâÊÑèÂ∑Æ„Å™„Åó„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "495\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "496\n",
      "-----\n",
      "\"~19% of cancer patients harbor RAS mutations\" per recent study in #CancerResearch @AACR journal. Not so much the 30% quoted historically. Wide variability across cancers.... #AACR20 https://t.co/ylUH2mMMQW https://t.co/nr0TfPFGR9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "497\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "498\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "499\n",
      "-----\n",
      "Avances de #Vacuna cubana contra el c√°ncer, fueron presentados en colaboraci√≥n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituci√≥n, existe un convenio de colaboraci√≥n que est√° dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "500\n",
      "-----\n",
      "Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "501\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "502\n",
      "-----\n",
      "‚ÄúThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,‚Äù says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "503\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "504\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "505\n",
      "-----\n",
      "The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "506\n",
      "-----\n",
      "You can never be too respectful, so always err on the side of showing more, not less, respect. #pallonc #oncology #hapc #nursing\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "507\n",
      "-----\n",
      "#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert \n",
      "@PennMedicine @PennMedNews\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "508\n",
      "-----\n",
      "üÜï‚úÖ#CRCSM #LCSM #BCSM #Cancer #HPBCSM #StomachCancer #EsophagealCancer #ColorectalCancer #LungCancer #LynchSyndrome #PANCSM #ANCSM #ESOCSM #HNCSM #LYMSM #MELSM #PEDCSM  and agnostic dMMR/MSI-High indicationüëáüèº\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "509\n",
      "-----\n",
      "Off-the-shelf CAR-T therapy helps leukemia patients in a small, first-in-human trial https://t.co/LCblW4C8JG via @sxbegle  #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "510\n",
      "-----\n",
      "#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert \n",
      "@PennMedicine @PennMedNews\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "511\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "512\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "513\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "514\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "515\n",
      "-----\n",
      "Join #abcam for virtual #AACR20 next week, when Abcam‚Äôs scientific experts will discuss how to advance cancer research as well as current industry trends and challenges. New talks and Q&amp;A sessions daily, April 27- May 1. Program here: https://t.co/cA2rGPqpaV https://t.co/hki2X183Ng\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "516\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "517\n",
      "-----\n",
      "cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin @MayoClinic @AACR #AACR20 https://t.co/qWgCNPMA6E\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "518\n",
      "-----\n",
      "#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse pr√©coce de la mani√®re dont ce #CLCC s‚Äôest adapt√© pour g√©rer l‚Äô√©pid√©mie #COVID19\n",
      "@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "519\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 cancer patients have a 15% mortality . Is this good outcome notably related to the almost 10% of patients who received compassionate #Tocilizumab ? \n",
      "https://t.co/dRmW2rAHaG https://t.co/1kc0iD9VcV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "520\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "521\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "522\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "523\n",
      "-----\n",
      "#AACR20 Part I was a success. Huge congratulations to the entire @AACR team for this incredible #virtual effort! We look forward to part II in June, w/a special session on #COVID19 in #Cancer. But before that, looking forward to #ASCO20 @ASCO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "524\n",
      "-----\n",
      "Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "525\n",
      "-----\n",
      "Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "526\n",
      "-----\n",
      "Do you have a few minutes? Interested in ICC? Join our #VirtualEvent today for \"Introduction to #Immunocytochemistry: principles, protocol steps &amp; troubleshooting‚Äù with Antonella Galli. Join us daily as we stream our #AACR20 content, April 27- May 1. https://t.co/zW0EMb3fF3 https://t.co/a74UO0EFYv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "527\n",
      "-----\n",
      "Here‚Äôs what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "528\n",
      "-----\n",
      "#NOXXON Presents Latest Clinical Data From the Phase 1/2 #NOXA12 / #Keytruda¬Æ Combination Trial in #ColorectalCancer and #PancreaticCancer at the #AACR20 $ALNOX https://t.co/JMOXuY8FpI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "529\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "530\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "531\n",
      "-----\n",
      "@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm\n",
      "\n",
      "Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1\n",
      "\n",
      "Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant\n",
      "\n",
      "https://t.co/bLGxRlKKu1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "532\n",
      "-----\n",
      "We should immediately move to switch stable patients to q6 week pembro, will be a big help in reducing unnecessary visits! #COVID„Éº19 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "533\n",
      "-----\n",
      "STAT story on this Gracell allo data. Definitely one of the more intriguing things we saw at #AACR20. https://t.co/EQJ9wzHiJk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "534\n",
      "-----\n",
      "#IntelliaTherapeutics to Present New Preclinical Data from¬†Its¬†#CRISPR/#Cas9 Programs¬†at the 23rd Annual¬†Meeting of the #AACR20 $NTLA https://t.co/jWIl5t7x3I\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "535\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "536\n",
      "-----\n",
      "#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert \n",
      "@PennMedicine @PennMedNews\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "537\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "538\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "539\n",
      "-----\n",
      "Today's #AACR20's plenary session is #COVID19 and #Cancer. Tune in to hear from MSK's Dr. Louis Voigt, as he presents \"#COVID19 and cancer: Flattening the curve but widening disparities.\" @AACR  https://t.co/JGQPnbAwHH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "540\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "‚¨ÜÔ∏è pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "541\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "542\n",
      "-----\n",
      "Today at 3:50pm tune in to #AACR20's minisymposium \"Evaluating #Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease,\" to hear from @KellyLBolton on \"Oncologic therapy shapes the fitness landscape of #ClonalHematopoiesis.\" https://t.co/OGd2f4qvSM https://t.co/PF7CXsVcvq\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "543\n",
      "-----\n",
      "It's day 2 of #AACR20. For more info on the virtual meeting &amp; what MSK experts will be featured please visit our website. @AACR https://t.co/qBHR2hbBy3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "544\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "545\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "546\n",
      "-----\n",
      "Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer https://t.co/m4Dr6kU662\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "547\n",
      "-----\n",
      "CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richter‚Äôs transformation is ongoing #lymsm https://t.co/aJwPboXCDS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "548\n",
      "-----\n",
      "New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "549\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "550\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "551\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "552\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "553\n",
      "-----\n",
      "#AACR20 news: Camrelizumab‚Äìapatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "554\n",
      "-----\n",
      "ÈáçË¶ÅÔºÅ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "555\n",
      "-----\n",
      "#AACR20 news: Camrelizumab‚Äìapatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "556\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "557\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "558\n",
      "-----\n",
      "#AACR20 news: Camrelizumab‚Äìapatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "559\n",
      "-----\n",
      "Ê≠¶Êº¢„Åã„Çâ„ÅÆÂ§öÊñΩË®≠Âæå„ÇçÂêë„ÅçÁ†îÁ©∂„ÄÇ\n",
      "‚òëÔ∏è„Åå„ÇìÊÇ£ËÄÖ„ÅØÊ≠ª‰∫°„ÇíÂê´„ÇÅ„ÅüÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èË°ÄÊ∂≤ËÖ´Áòç„Å®ËÇ∫Áôå„ÄÅÁóÖÊúüStageIV„ÅÆ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èÊ≤ªÁôÇÊ≥ï„Åß„ÅØ„ÄÅÊâãË°ì„ÇÑÂÖçÁñ´„ÉÅ„Çß„ÉÉ„ÇØ„Éù„Ç§„É≥„ÉàÈòªÂÆ≥Ëñ¨„ÅØÊúâÊÑè„Å´ÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÅÆÊúâÁÑ°„Åß„ÅØÊúâÊÑèÂ∑Æ„Å™„Åó„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "560\n",
      "-----\n",
      "Ê≠¶Êº¢„Åã„Çâ„ÅÆÂ§öÊñΩË®≠Âæå„ÇçÂêë„ÅçÁ†îÁ©∂„ÄÇ\n",
      "‚òëÔ∏è„Åå„ÇìÊÇ£ËÄÖ„ÅØÊ≠ª‰∫°„ÇíÂê´„ÇÅ„ÅüÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èË°ÄÊ∂≤ËÖ´Áòç„Å®ËÇ∫Áôå„ÄÅÁóÖÊúüStageIV„ÅÆ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇ\n",
      "‚òëÔ∏èÊ≤ªÁôÇÊ≥ï„Åß„ÅØ„ÄÅÊâãË°ì„ÇÑÂÖçÁñ´„ÉÅ„Çß„ÉÉ„ÇØ„Éù„Ç§„É≥„ÉàÈòªÂÆ≥Ëñ¨„ÅØÊúâÊÑè„Å´ÈáçÁóáÂåñ„É™„Çπ„ÇØ„ÅåÈ´ò„ÅÑ„ÄÇÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÅÆÊúâÁÑ°„Åß„ÅØÊúâÊÑèÂ∑Æ„Å™„Åó„ÄÇ https://t.co/ltEwNXcliw\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "561\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ https://t.co/OFppgUN3XK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "562\n",
      "-----\n",
      "New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer https://t.co/41pUGEvmeG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "563\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "564\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "565\n",
      "-----\n",
      "@n8pennell Lung cancer pts seem to do worse as a subgroup. \n",
      "\n",
      "@AACR #AACR20 \n",
      "\n",
      "Pts with lung cancer, hematologic cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events.\n",
      "\n",
      "https://t.co/cgqZIOWSUl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "566\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "567\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "568\n",
      "-----\n",
      "People with #LynchSyndrome are more likely to develop #colorectalcancer. But, a study led by our @evilarsan shows taking naproxen daily may reduce that risk: https://t.co/5RNLdY3TGk #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "569\n",
      "-----\n",
      "Great timing after #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "570\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "571\n",
      "-----\n",
      "Great jo @GustaveRoussy team! https://t.co/i6raJVTpWt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "572\n",
      "-----\n",
      "El futuro del diagn√≥stico del c√°ncer. M√°s inversi√≥n en investigaci√≥n en sistemas de cribado y en diagn√≥stico en fases tempranas salvar√≠a m√°s vidas que cualquier nuevo tratamiento\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "573\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "574\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "575\n",
      "-----\n",
      "New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "576\n",
      "-----\n",
      "Positive preclinical and FIH data presented for IPN-60090, a potent GLS1 inhibitor for the oral treatment of KEAP1/NFE2L2-mutant NSCLC and ASNS-low HGSOC under joint development by MD Anderson Center and Ipsen. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "577\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "578\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "579\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "580\n",
      "-----\n",
      "A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "581\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "582\n",
      "-----\n",
      "#AACR20 #COVID19 https://t.co/NLnCsxOEvt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "583\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ https://t.co/OFppgUN3XK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "584\n",
      "-----\n",
      "Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated non‚Äìsmall cell lung cancer harboring an EGFR exon 20 insertion.\n",
      "https://t.co/DnJFvZUxr0 #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "585\n",
      "-----\n",
      "Syndax Pharmaceuticals presents preliminary phase I data for SNDX-5613, their lead menin/MLL interaction inhibitor for the oral treatment of MLL-rearranged (MLL-r) and NPM1-mutant acute leukemias; responses observed in two patients with MLL-r acute leukemia. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "586\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "587\n",
      "-----\n",
      "„ÄåÊ≥®ÁõÆ„Åô„Åπ„Åç„ÅØ„ÄÅÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Åü„Åå„ÇìÊÇ£ËÄÖ„ÅØ„ÄÅÈùûÊãÖ„Åå„ÇìÊÇ£ËÄÖ„Å´ÊØîËºÉ„Åó„Å¶„ÄÅ(Ë®≥Ê≥®:COVID-19„Å´Èñ¢„Åó„Å¶)ÈáçÁóá„Å´„Å™„Çã„Åã„Å©„ÅÜ„Åã„Å´„ÄÅÁµ±Ë®àÂ≠¶ÁöÑÊúâÊÑèÂ∑Æ„ÅØÁÑ°„Åã„Å£„Åü„Äç\n",
      "\n",
      "ASTRO(Á±≥ÂõΩÊîæÂ∞ÑÁ∑öËÖ´ÁòçÂ≠¶‰ºö)„Åå #AACR20 (2020Âπ¥„ÅÆ„Ç™„É≥„É©„Ç§„É≥ÈñãÂÇ¨„Åï„Çå„ÅüÁ±≥ÂõΩ„Åå„ÇìÂ≠¶‰ºö)„ÅßÁô∫Ë°®„Åï„Çå„ÅüÊ≠¶Êº¢„ÅÆÂ§ßÂ≠¶ÁóÖÈô¢„Åã„Çâ„ÅÆ„Éá„Éº„Çø„ÇíÂºïÁî®„Åó„Å¶„ÅÑ„Åæ„Åô„ÄÇ https://t.co/OFppgUN3XK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "588\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "589\n",
      "-----\n",
      "A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "590\n",
      "-----\n",
      "Haneen Shalabi @NCI_CCR_PedOnc presented her team's findings at yesterday's virtual #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "591\n",
      "-----\n",
      "The @AML_Hub disseminates the latest evidence-based information on acute myeloid #leukemia. Proud to be recognized again as a top #leusm influencer during #AACR20! ‚¨áÔ∏è https://t.co/XVLb5wpEAu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "592\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "593\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "594\n",
      "-----\n",
      "Haneen Shalabi @NCI_CCR_PedOnc presented her team's findings at yesterday's virtual #AACR20. Read more https://t.co/MBdU2T0r7n via @onclive\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "595\n",
      "-----\n",
      "Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "596\n",
      "-----\n",
      "#AACR20 starts as a virtual meeting with 54,000 ppl\n",
      "\n",
      "An important meeting held in this format:\n",
      "Should others follow?\n",
      "\n",
      "üëâNo facility/flight expenses\n",
      "üëâReduced environment impact\n",
      "üëâReduce $ to register\n",
      "üëâMore can participate globally\n",
      "üëâMore important information disseminated https://t.co/OPSjKPNWsG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "597\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "598\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "599\n",
      "-----\n",
      "WATCH: Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer @YaleCancer @AACR #bcsm #AACR20 https://t.co/8aJEhb74Lf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "600\n",
      "-----\n",
      "IMspire150 just presented at #AACR20 in metastatic #melanoma. Important PFS data up to 12m which may help individualize selection of initial therapies for BRAFmut pts. Longer FU to access who are the long responders (PD1 driven only? or synergistic effect?) is needed. https://t.co/I5gJ5C0BVr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "601\n",
      "-----\n",
      "Unbelievably unacceptable presentation going on by @cityofhope.  Lung cancer is preventable? Tell that to @VirginiaMByrne (dead- no risk factors). Or tell it to me (neversmoker) #aacr20, you can do better. #lcsm https://t.co/13lloILxmU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "602\n",
      "-----\n",
      "Baller co-fellow, physician-scientist, and desk neighbor @JZimmermanMDPhD presents her work at #AACR20 virtually:\n",
      "''miR-21 inhibition in mice models of pancreatic cancer''\n",
      "\n",
      "She talks organoids, I talk OCM, @jaffeejaffee/ @laherda mentor both. Incredible to be at @hopkinskimmel! https://t.co/om7WtTTHj2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "603\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "604\n",
      "-----\n",
      "STK11 and KEAP1 mutations in KEYNOTE-042. STK11 mutation a/w lower PD-L1 expression. Pembro a/w better outcomes compared with chemo, regardless of STK11 or KEAP1 mutation status. Very low ORR with chemo in STK11 mutation+ NSCLC.\n",
      "#AACR20 @OncoAlert https://t.co/Nqe7NetuCO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "605\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "606\n",
      "-----\n",
      "Facing previous data suggesting imunorresistance, this small exploratory analysis of KN042 exhibits IO monotherapy benefit for PDL1 &gt; 1% patients regardless of STK11/KEAP1 status. Nevertheless it seems insufficient to encourage mono IO as 1L for STK11/KEAP1 mut NSCLC. #AACR20 https://t.co/QviVJqAId1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "607\n",
      "-----\n",
      "What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the world‚Äôs largest webinar (can‚Äôt wait to see demographic data);\n",
      "2. KRAS is Undrugged (*yet*), not Undruggable;\n",
      "3. BRAF is the ultimate Hydra;           4. @AACR really came throughüëç\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "608\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "609\n",
      "-----\n",
      "WATCH: Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer @YaleCancer @AACR #bcsm #AACR20 https://t.co/8aJEhb74Lf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "610\n",
      "-----\n",
      "Good news for #EGFR #exon20 patients! FDA granted Breakthrough Therapy Designation for @TakedaOncology  mobocertinib (TAK-788) for patients w/ #EGFR #exon20 after platinum-based chemotherapy. Will be discussed tomorrow at #AACR20 #LCSM @EGFRResisters @Exon20Group\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "611\n",
      "-----\n",
      "I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "612\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "613\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "614\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "615\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "616\n",
      "-----\n",
      "Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "617\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "618\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "619\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "620\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "621\n",
      "-----\n",
      "STOP patient shaming! If you must say ‚Äúprevention‚Äù, consider using the more accurate phrase of ‚Äúrisk reduction.‚Äù\n",
      "\n",
      "As a vegetarian for 20 yrs, avid half marathoner, no history of #breastcancer, &amp; diagnosed #metastatic at 34- my cancer was not preventable.\n",
      "\n",
      "#BCSM #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "622\n",
      "-----\n",
      "TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "623\n",
      "-----\n",
      "Being presented NOW at #AACR20 Virtual Annual Meeting Plenary Session on #COVID19 and Cancer!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "624\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "625\n",
      "-----\n",
      "As an #IM resident I am pleased to watch #AACR20 live stream virtual meeting while preparing my shift fighting #COVID19 ü•ä Thank to all who is making this happen @AACR @Rick__Buck @AACRPres &amp; who increased awareness @cancerassassin1 @Aiims1742 @DrSGraff @tmprowell  @OncoAlert üëèüèª https://t.co/Dj9U74w9Tm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "626\n",
      "-----\n",
      "Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "627\n",
      "-----\n",
      "Thank you so much to the #AACR20 organizers for making this possible: kudos for organizing a seamless event even in the face of #COVID19 . Very thoughtful discussion, tons of participation from the audience and some very cool #cancer tweep connections. See y'all tomorrow! https://t.co/tUxR4msXCN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "628\n",
      "-----\n",
      "Regarding response assessment, ctDNA exhibit more eminent clinical application. Exploratory analysis from FLAURA correlate ctDNA clearance w/ ‚¨ÜÔ∏èPFS. Could a individualized approach w/ early ctDNA reassessment guide the decision of escalating or de-escalating treatment? #AACR20 https://t.co/qgv3RC5eq1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "629\n",
      "-----\n",
      "It's weird not hearing standard applause from the audience as we would have otherwise in person at #AACR20. Maybe after each Virtual Presentation, we should post GIFs instead.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "630\n",
      "-----\n",
      "KRAS/RAS co-occurrence and mutual exclusivity by tumor types. STK11, ATM, KEAP1 have high co-occurrence patterns with KRAS mutated NSCLC #AACR20 https://t.co/2II78VFUwc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "631\n",
      "-----\n",
      "This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "632\n",
      "-----\n",
      "Live #AACR20 Study from @MDAndersonNews Shows how Taking Naproxenüíädaily may reduce the risk of developing #Colorectalcancer in people with #lynchSyndrome @OncoAlert üö®#CRC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "633\n",
      "-----\n",
      "#OncoAlert #AACR20 Dr. Carlos Gomez-Martin presents #COVID19 data from Hospital 12 de Octubre in Madrid, Spain. Data slides not posted at his request but of note: higher proportion of patients with lung cancer, mortality 25%, radiographic changes common, neutropenia a major risk. https://t.co/s9JOTPgEur\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "634\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "‚¨ÜÔ∏è pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "635\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "636\n",
      "-----\n",
      "At #AACR20, Dr Jimeno presents data on mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding OX40L, made for tumor injection, given alone or with the PD-L1 inhibitor durvalumab. https://t.co/JPXn4wjlrT\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "637\n",
      "-----\n",
      "Phase I study of COM701 (PVRIG targeting Ab) monoTx (Arm A) or in combo with nivolumab (Arm B). N=28. No DLTs in both arms. PR seen in primary peritoneal cancer (n=1) and MSS-CRC (n=1). Interesting target deserving further evaluation. #AACR20 https://t.co/zqPjjEVsQF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "638\n",
      "-----\n",
      "Clinical activity of TAK-788 - 160 mg qd recommended dose for Phase II #AACR20 https://t.co/BbjUFD1vJD\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "639\n",
      "-----\n",
      "Ha! I spy with my little eye... that I am on the list of #AACR20 influencers! ü§©ü§ì Just did a profile pic change right in time , so look out for my former me\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "640\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "641\n",
      "-----\n",
      "First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "642\n",
      "-----\n",
      "Bispecifics @ #AACR20 | Bispecific abstract (5672) for ABBV-428 mesothelin (MSLN) x CD40 BiAb https://t.co/2gdFvO2akk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "643\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "644\n",
      "-----\n",
      "Early cancer detection &amp; ctDNA session: still hold more questions than answers. Specificity was the presenters‚Äô focus but concerns regarding sensibility (including positive patients demanding rule-out tests) &amp; optimal test schedule to magnify cost-effectiveness yet exist. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "645\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "646\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "647\n",
      "-----\n",
      "The @lymphomahub aims to lift levels of knowledge in #lymphoma and CLL. We are proud to be recognized as a top #lymsm influencer during #AACR20!‚¨áÔ∏è https://t.co/pDRKMo3Gz0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "648\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "649\n",
      "-----\n",
      "Experimental blood test helped detect women's cancers early, study finds. But it missed many more cancers than it found, raised false alarms, &amp; only looked at ages 65-75, @MMarchioneAP - https://t.co/K1DGMdcE5J @DrLen #womenshealth #AACR20 @ScienceMagazine https://t.co/jkeSxv5I9S\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "650\n",
      "-----\n",
      "ÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Å¶„ÇÇCovid-19ÊÑüÊüì„Å´ÂØæ„Åô„ÇãÂÖçÁñ´Ê©üËÉΩ„ÅØËêΩ„Å°„Å™„ÅÑ„Çà„ÅÜ„Åß„ÅôÔºàËÇ∫„Åå„Çì„Å´„Å§„ÅÑ„Å¶„ÅØÊú™Áü•Ôºâ„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "651\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "652\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "653\n",
      "-----\n",
      "ÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Å¶„ÇÇCovid-19„Å´ÂØæ„Åô„ÇãÂÖçÁñ´Ê©üËÉΩ„ÅØËêΩ„Å°„Å™„ÅÑ„Åø„Åü„ÅÑÔºàËÇ∫„Åå„Çì„Å´„Å§„ÅÑ„Å¶„ÅØÊú™Áü•Ôºâ„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "654\n",
      "-----\n",
      "One more time for the folks in the back‚Äî #WordsMatter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "655\n",
      "-----\n",
      "Look forward to seeing the entire study in print, but fortunately we got a glimpse at #AACR20: https://t.co/iUIuu99rEo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "656\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "657\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination‚Äôs activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "658\n",
      "-----\n",
      "Tumor mutation burden (TMB) high and low in human tumors, AACR2020\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "659\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @CharuAggarwalMD üë©‚Äç‚öïÔ∏èfrom @PennCancer  Virtually Live at #AACR20 discussing globalüåèpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino üáÆüáπ&amp; The French experience by @barlesi from @GustaveRoussy üá´üá∑\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "660\n",
      "-----\n",
      "Our @OncoAlert üö®Colleague @CharuAggarwalMD üë©‚Äç‚öïÔ∏èfrom @PennCancer  Virtually Live at #AACR20 discussing globalüåèpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino üáÆüáπ&amp; The French experience by @barlesi from @GustaveRoussy üá´üá∑\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "661\n",
      "-----\n",
      "‚ö°Ô∏èCheck the recent publication @NatureCancer by @corsellos @toddgolub1 on discovering the anticancer potential of non-oncology drugs - it's a must read!\n",
      "\n",
      "https://t.co/ZGW16wtDhd\n",
      "https://t.co/ARXAr4WWq7 \n",
      "\n",
      "#AACR20 https://t.co/Jm3a9zrgWD https://t.co/y87gdeLIet\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "662\n",
      "-----\n",
      "This is hugeüëáüèº\n",
      "\n",
      "#Immunotherapy dosing esp amidstüí° on how to ‚¨áÔ∏èexposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 \n",
      "\n",
      "@US_FDA @FDAOncology Approves @Merck #KEYTRUDA‚ûñ#pembrolizumab\n",
      "\n",
      "‚û°Ô∏è400 mg Q6Ô∏è‚É£Weeks‚úÖ\n",
      "\n",
      "#OncoAlert \n",
      "https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "663\n",
      "-----\n",
      "#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert \n",
      "@PennMedicine @PennMedNews\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "664\n",
      "-----\n",
      "ÊîæÂ∞ÑÁ∑öÊ≤ªÁôÇ„ÇíÂèó„Åë„Å¶„ÇÇCovid-19„Å´ÂØæ„Åô„ÇãÂÖçÁñ´Ê©üËÉΩ„ÅØËêΩ„Å°„Å™„ÅÑ„Åø„Åü„ÅÑÔºàËÇ∫„Åå„Çì„Å´„Å§„ÅÑ„Å¶„ÅØÊú™Áü•Ôºâ„ÄÇ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "665\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "666\n",
      "-----\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "667\n",
      "-----\n",
      "@OncologyNursing #clinicaltrials Can ship oral #cancer agents - injectable agents must be administered at a registered @FDA site @theNCI #AACR2020\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "668\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "669\n",
      "-----\n",
      "Why aren‚Äôt all medicines taken as pills? Teresa Klinowska, Global Project Leader in Oncology, explains some of the decisions that go into how medicines are developed. #SciencefromAtoZ #AACR20 https://t.co/yuoe3QQtf1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "670\n",
      "-----\n",
      "ICYMI ‚Äì Special Collection of Reviews on #Cancer Cell Biology #AACR20: https://t.co/6J6PUDn4r4 https://t.co/LZzZy11mu5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "671\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "672\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "673\n",
      "-----\n",
      "Includes #cancer #survivorship research @OncologyNursing @theNCI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "674\n",
      "-----\n",
      "Thanks @weoncologists \n",
      "Cc: @MGHThoracicOnc @EGFRResisters @Exon20Group\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "675\n",
      "-----\n",
      "Link to our recent paper. Great work by Liam Spurr @lfspurr, Giuseppe Lamberti @GLambertiMD with wonderful leadership by Andy Cherniack and Mark Awad. https://t.co/WIg6vm0JX4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "676\n",
      "-----\n",
      "New prospective data on outcomes with IO for NSCLC based on STK11 and KEAP1 status. Certainly limitations with only subset with available NGS results. Some of my best IO responders have been 2 STK11-mut patients. Not ready to skip IO for these patients yet. #AACR20 #LCSM https://t.co/1T8Mwt9hTu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "677\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "678\n",
      "-----\n",
      "Thanks for the coverage of our @SWOG trial results presented at #AACR20, @jasoncology and @OncLive!\n",
      "https://t.co/av8vGk7toM via @onclive\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "679\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaci√≥n, desarrollo y producci√≥n de medicamentos, presenta prometedores resultados de ensayo cl√≠nico en congreso sobre oncolog√≠a. Otra demostraci√≥n del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "680\n",
      "-----\n",
      "Just Outüì£at @NEJM üì∞In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesüß¨w/a role in homologous recombination repair, olaparib was associated w/longer PFS‚ÄºÔ∏è #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "681\n",
      "-----\n",
      "@Jbauml @StephenVLiu . In looking at #COVID19 in #lcsm @ #AACR20, was any data presented on egfr/alk/ros mutation? Is it truly lung cancer that was the risk factor or was lung cancer a surrogate for pre-existing lung disease?\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "682\n",
      "-----\n",
      "Important. We started doing it when pandemic came to Ireland.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "683\n",
      "-----\n",
      "üì¢ Pr Fabrice @barlesi @GustaveRoussy a pr√©sent√© en pl√©ni√®re #Covid19etCancer du congr√®s #AACR20 une analyse pr√©coce de la situation et la mani√®re dont Gustave Roussy s‚Äôest adapt√© avec agilit√© pour g√©rer l‚Äô√©pid√©mie de #covid19.\n",
      "\n",
      "Lire le communiqu√© : https://t.co/VPFdDJgHol\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "684\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "685\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "686\n",
      "-----\n",
      "@n8pennell 1) n=107 likely not large enough for multivariate analysis, 2) XRT &amp; Pneumonitis - see: \n",
      "Pneumonitis incidence in NSCLC Tx'd w/ immunotherapy or chemo in clinical trials &amp; real-world data [Apr 27, 2020 ] Liu et al. #AACR20 CT086 - VCTPL08 - https://t.co/VkpILtNFbu #lcsm #irAE\n",
      "\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "my_dict=[]\n",
    "index_list=[]\n",
    "name_list=[]\n",
    "date_list=[]\n",
    "val=1\n",
    "for x in data:\n",
    "    print(str(val)+'\\n-----')\n",
    "    if 'retweeted_status' not in x:\n",
    "        if 'extended_tweet' not in x:\n",
    "            y=x['text']\n",
    "            print(y)\n",
    "        else:\n",
    "            y=x['extended_tweet']['full_text']\n",
    "            print(y)\n",
    "    else:\n",
    "        if 'extended_tweet' not in x['retweeted_status']:\n",
    "            y=x['retweeted_status']['text']\n",
    "            print(y)\n",
    "        else:\n",
    "            y=x['retweeted_status']['extended_tweet']['full_text']\n",
    "            print(y)\n",
    "    print('\\n\\n\\n')\n",
    "    my_dict.append(y)\n",
    "    index_list.append(val)\n",
    "    name_list.append(x['user']['name'])\n",
    "    date_list.append(x['created_at'])\n",
    "    val+=1\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "columns=[\"Index\",\"Date\",\"Name\",\"Tweet\"]\n",
    "my_df=pd.DataFrame(columns=columns)\n",
    "my_df['Index']=index_list\n",
    "my_df['Date']=date_list\n",
    "my_df['Name']=name_list\n",
    "my_df['Tweet']=my_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "my_df.to_excel('SecondPhase.xlsx', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
